In the first-ever efficacy trial of antiretroviral-based pre-exposure prophylaxis, once-daily oral tenofovir significantly reduced the risk for HIV acquisition among men who have sex with men. The use ...
Real-world data show DoxyPEP implementation among PrEP users significantly reduces the incidence of chlamydia and syphilis.
MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...
A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...
PLANO, Texas, Jan. 22, 2026 /PRNewswire/ -- Q Care Plus, a telehealth provider known for its leadership in providing HIV ...
In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the ...
There was an increase in the annual number of PrEP users from 10,281 in 2013 to 505,730 in 2023. HealthDay News — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a ...
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis who were prescribed preexposure prophylaxis (PrEP), a preventative ...
Pre-exposure prophylaxis clinical trials of a 3-dose regimen of Verorab® followed by a booster dose at 1 year in adults and children achieved an adequate immune response.1 Of those who had a booster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results